title: [Assessment of dose-dependent effect during phlebotropic therapy of chronic diseases of lower-limb veins].
abstract: Described herein are the findings of an open, prospective, comparative study of 2-month use of Antistax in a total of one hundred and nineteen patients presenting with clinical manifestations of chronic venous disease of class C0 (60 subjects) and class C2,3 (59 patients). Each group was subdivided into two subgroups of patients receiving Antistax at a daily dose of 360 and 720 mg, respectively. The authors studied the dynamics of the extremity's volume during direct plethysmography by means of liquid displacement, measuring the extremity's circumference under the ankles and in the muscular portion of the crus. The degree of subjective symptoms of CVI (increased fatigue of the legs and pain) was assessed by means of a 10-point visual analogue scale. The points of the study were the baseline state and the condition 2 months after medicamentous therapy. It was determined that administration of Antistax at daily doses of 360 and 720 mg for 2 months resulted in a significant decrease in the volume of the affected extremity, which was accompanied by regression of complaints related to venous insufficiency. The patients with class C0 and C2,3 CVI showed a pronounced dose-dependent effect, being more significant in class C2,3 CVI. We conceive it to be expedient that patients presenting with clinically pronounced variants of CVI inducing an increase in the extremity's volume should be given Antistax at a daily dose of 720 mg.
authors.forename: Iu T
authors.initials: IuT
authors.lastname: Tsukanov
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Tsukanov
authors.forename: V V
authors.initials: VV
authors.lastname: Vasilevich
mesh_terms: D000328:Adult; D000368:Aged; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011794:Quercetin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016896:Treatment Outcome; D014689:Venous Insufficiency / Q000188:drug therapy*; D055815:Young Adult
chemical_list: C522873:Antistax; D011794:Quercetin